412 related articles for article (PubMed ID: 16413248)
1. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
Jones RW; Bayer A; Inglis F; Barker A; Phul R
Int J Geriatr Psychiatry; 2007 Mar; 22(3):258-62. PubMed ID: 17243195
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of repaglinide in subjects with renal impairment.
Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P
Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
6. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
7. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.
Lefèvre G; Duval M; Gauron S; Brookman LJ; Rolan PE; Morris TM; Piraino AJ; Morgan JM; Palmisano M; Close P
Clin Pharmacol Ther; 1997 Jul; 62(1):50-9. PubMed ID: 9246019
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
10. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Smith W; Swan S; Marbury T; Henney H
J Clin Pharmacol; 2010 Feb; 50(2):151-9. PubMed ID: 19966074
[TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function.
Nagy CF; Kumar D; Cullen EI; Bolton WK; Marbury TC; Gutierrez MJ; Hutman HW; Pratt RD
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):18-24. PubMed ID: 15496219
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.
Yao C; Raoufinia A; Gold M; Nye JS; Ramael S; Padmanabhan M; Walschap Y; Verhaeghe T; Zhao Q
J Clin Pharmacol; 2005 May; 45(5):519-28. PubMed ID: 15831775
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients.
Turpie AG; Lensing AW; Fuji T; Boyle DA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):114-21. PubMed ID: 19339838
[TBL] [Abstract][Full Text] [Related]
15. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Jerling M; Abdallah H
Clin Pharmacol Ther; 2005 Sep; 78(3):288-97. PubMed ID: 16153399
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
[TBL] [Abstract][Full Text] [Related]
17. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of sparfloxacin in patients with renal impairment.
Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
[TBL] [Abstract][Full Text] [Related]
19. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
[TBL] [Abstract][Full Text] [Related]
20. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Layton G; Leclerc V; Weil A
Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
